Literature DB >> 15869616

The poor quality of streptokinase products in use in developing countries.

C Longstaff, C Thelwell, C Whitton.   

Abstract

Mesh:

Substances:

Year:  2005        PMID: 15869616     DOI: 10.1111/j.1538-7836.2005.01271.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  4 in total

1.  Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction.

Authors:  Blas Y Betancourt; María A Marrero-Miragaya; Giset Jiménez-López; Carmen Valenzuela-Silva; Elizeth García-Iglesias; Francisco Hernández-Bernal; Francisco Debesa-García; Tania González-López; Leovaldo Alvarez-Falcón; Pedro A López-Saura
Journal:  BMC Clin Pharmacol       Date:  2005-11-02

2.  Screening, Cloning and Expression of Active Streptokinase from an Iranian Isolate of S.equisimilis Group C in E. coli.

Authors:  Malihe Keramati; Farzin Roohvand; Mohammad Mehdi Aslani; Shohreh Khatami; Mohammadreza Aghasadeghi; Mehdi Sadat; Arash Memarnejadian; Fatemeh Motevalli
Journal:  Iran J Basic Med Sci       Date:  2013-04       Impact factor: 2.699

3.  Biological activity analysis of native and recombinant streptokinase using clot lysis and chromogenic substrate assay.

Authors:  Arash Mahboubi; Seyyed Kazem Sadjady; Mohammad Mirzaei Saleh Abadi; Saeed Azadi; Roya Solaimanian
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

4.  Biosimilars: the process is the product. The example of recombinant streptokinase.

Authors:  C Thelwell; C Longstaff
Journal:  J Thromb Haemost       Date:  2014-07-31       Impact factor: 5.824

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.